KMTS Kestra Medical Technologies, Ltd.

QT57

NASDAQ·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

29.01

-0.80-2.68%

Overview Short InterestFilings

KMTSQT57Kestra Medical Technologies, Ltd.·NASDAQ

Overview Short InterestFilings

29.01-2.68%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

LMAT-0.81%$80.60 XRAY-1.72%$9.73 AZTA+4.47%$37.14 STAA+0.92%$25.17 ATRC+0.89%$60.41 PLSE-1.32%$52.20 NVST+0.24%$24.77 ICUI-0.34%$161.83

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.67	Insider Own	2.28%	Shs Outstand	59.56M	Perf Week	-3.27%

Market Cap	1.78B	Forward P/E	—	EPS next Y	-2.05	Insider Trans	-38.08%	Shs Float	33.72M	Perf Month	2.36%

Enterprise Value	1.65B	PEG	—	EPS next Q	-0.61			Short Float	10.17%	Perf Quarter	15.76%

Income	-150.00M	P/S	16.44	EPS this Y	—			Short Ratio	10.24	Perf Half Y	43.26%

Sales	108.00M	P/B	8.00	EPS next Y	—	ROA	-43.15%	Short Interest	3.43M	Perf YTD	9.39%

Book/sh	3.73	P/C	8.92	EPS next 5Y	—	ROE	-64.18%	52W High	31.06 -6.60%	Perf Year	5.95%

Cash/sh	3.34	P/FCF	—	EPS past 3/5Y	—	ROIC	-47.98%	52W Low	17.34 67.30%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	128.15% —	Gross Margin	53.89%	Volatility	4.97% 5.69%	Perf 5Y	—

Dividend TTM	—	EV/Sales	15.30	EPS Y/Y TTM	—	Oper. Margin	-134.48%	ATR (14)	1.56	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	4.69	Sales Y/Y TTM	63.64%	Profit Margin	-140.43%	RSI (14)	53.88	Recom	2.20

Dividend Gr. 3/5Y	—	Current Ratio	4.69	EPS Q/Q	-63.04%	SMA20	2.70%	Beta	1.50	Target Price	31.50

Payout	—	Debt/Eq	0.34	Sales Q/Q	63.16%	SMA50	8.28%	Rel Volume	1.46	Prev Close	29.81

Employees	443	LT Debt/Eq	0.34	Earnings	Dec 10	SMA200	21.48%	Avg Volume	368.49K	Price	29.01

IPO Date	Mar 06, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.78% 6.76%	Net Debt/EBITDA	—	Volume	537,361	Change	-2.68%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-20-26	Initiated	Evercore ISI	Outperform	$34
Sep-15-26	Reiterated	RBC Capital		$30
Jul-15-26	Reiterated	Wolfe Research		$30
Jul-15-26	Reiterated	BTIG	Buy	$32
Jan-16-26	Reiterated	Goldman Sachs	Neutral	$27 → $24
Jan-09-26	Reiterated	Goldman Sachs	Neutral	$25 → $27
Dec-12-25	Reiterated	Stifel Nicolaus		$28 → $30
Dec-12-25	Reiterated	Piper Sandler	Overweight	$30
Dec-12-25	Reiterated	Wells Fargo	Overweight	$28

Latest News· Times ET

Oct-30-26

Oct-30-2606:00AM

Kestra Medical Technologies to Participate in Upcoming Investor Conferencesglobenewswire.com

Oct-20-26

Oct-20-2604:35AM

Evercore ISI Group Initiates Coverage On Kestra Medical Techs with Outperform Rating, Announces Price Target of $34Benzinga

Oct-12-26

Oct-12-2601:44AM

Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)defenseworld.net

Oct-01-26

Oct-01-2606:01AM

Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – Should You Buy?defenseworld.net

06:00AM

Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companiesglobenewswire.com

Sep-21-26

Sep-21-2610:10PM

Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue OutlookYahoo

Sep-17-26

Sep-17-2605:14PM

Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?Yahoo

Sep-16-26

Sep-16-2607:45AM

Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizonseekingalpha.com

01:21AM

Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Missdefenseworld.net

Sep-15-26

Sep-15-2608:02AM

Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com

02:11AM

Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcriptseekingalpha.com

Sep-14-26

Sep-14-2606:26PM

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimateszacks.com

06:04PM

Kestra Medical Technologies Q1 Earnings Call Highlightsmarketbeat.com

04:01PM

Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Resultsglobenewswire.com

Sep-11-26

Sep-11-2602:01AM

Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga

Company

Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2026 4/30/2026	FY 2025 4/30/2025	FY 2024 4/30/2024	FY 2023 4/30/2023	FY 2021 4/30/2021	FY 2020 4/30/2020
Total Revenue	108	95	60	28	—	—	—
Cost of Goods Sold Incl. D&A	49	46	36	27	—	—	—
Gross Profit	57	49	24	0	—	—	—
Selling, General and Administrative Excl. Other	178	164	115	70	—	—	—
Research and Development	23	19	16	15	—	—	—
Other Operating Expense	0	1	0	0	—	—	—
Operating Income	-144	-135	-106	-85	—	—	—
Interest Expense	8	8	8	6	—	—	—
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	3	11	0	-3	—	—	—
Net Income Before Taxes	-150	-131	-114	-94	—	—	—
Income Taxes	0	0	0	0	—	—	—
Consolidated Net Income	-150	-132	-114	-94	—	—	—
Net Income From Continuing Operations	-150	-132	-114	-94	—	—	—
Net Income	-150	-132	-114	-94	—	—	—
EPS (Recurring)	-2.67	-2.43	-5.13	-2.04	—	—	—
EPS (Basic, Before Extraordinaries)	-2.67	-2.43	-5.13	-2.04	—	—	—
EPS (Diluted)	-2.67	-2.43	-5.13	-2.04	—	—	—
EBITDA	-130	-137	-98	-76	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	15.85	12.65	20.05	—	—	—	—
Gross Margin	52.78	51.58	40.00	0.00	—	—	—
Operating Margin	-133.33	-142.11	-176.67	-303.57	—	—	—
Net Margin	-138.89	-138.95	-190.00	-335.71	—	—	—
Shares Outstanding	59	58	50	50	—	—	—
Market Capitalization	1,712	1,202	1,203	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mahboob Vaseem	Chief Financial Officer	Oct 29 '26	Sale	30.60	4,788	146,503	60,609	Oct 29
Mahboob Vaseem	Chief Financial Officer	Oct 29 '26	Option Exercise	17.00	4,788	81,396	65,397	Oct 29
Mahboob Vaseem	Chief Financial Officer	Oct 28 '26	Sale	30.48	39,903	1,216,303	60,609	Oct 29
Mahboob Vaseem	Chief Financial Officer	Oct 28 '26	Option Exercise	17.00	39,903	678,351	100,512	Oct 29
Umberger Traci S	Director, Officer	Oct 27 '26	Sale	30.03	30,000	900,882	195,825	Oct 29
Mahboob Vaseem	Chief Financial Officer	Oct 27 '26	Sale	30.04	34,809	1,045,784	60,609	Oct 29
Mahboob Vaseem	Chief Financial Officer	Oct 27 '26	Option Exercise	17.00	34,809	591,753	95,418	Oct 29
Umberger Traci S	Director, Officer	Oct 27 '26	Option Exercise	17.00	30,000	510,000	225,825	Oct 29
Umberger Traci S	Director, Officer	Oct 21 '26	Sale	27.18	100,000	2,718,318	195,825	Oct 22
Umberger Traci S	Director, Officer	Oct 21 '26	Option Exercise	17.00	100,000	1,700,000	295,825	Oct 22
Webster Brian Daniel	Director, Officer	Oct 20 '26	Sale	29.56	15,000	443,389	445,215	Oct 22
COHEN RAYMOND W	Director	Sep 30 '26	Sale	29.28	3,330	97,504	54,790	Oct 01
Kwo Elizabeth	Director	Sep 21 '26	Sale	24.26	4,010	97,268	14,116	Sep 23
Reilly Kevin C	Director	Sep 08 '26	Sale	25.13	2,932	73,677	5,368	Sep 10
Schwartz Jeffrey Lawrence	Director, 10% Owner	Sep 08 '26	Sale	25.18	3,890	97,942	7,019	Sep 10

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.